Valye reports for unlimited access

Argan, Inc. operates as a holding company with wholly-owned subsidiaries focused on engineering and construction services across three main segments: Power, Industrial, and Teledata. The Power segment delivers comprehensive EPC services to power generation customers including independent power producers and utilities, with projects in the U.S., Ireland, and the U.K. This segment accounts for the majority of revenues and maintains a substantial project backlog. The Industrial segment provides on-site industrial construction and fabrication services primarily in the Southeastern U.S., serving diverse industrial customers. The Teledata segment offers utility construction and technology wiring solutions mainly in the Mid-Atlantic region. The company emphasizes strategic oversight while allowing subsidiaries operational independence. It manages risks related to labor, supply chain, and regulatory compliance, and competes with large and regional firms in its markets.

Farmers & Merchants Bancshares, Inc. is a financial services company that files regular reports with the SEC, including annual 10-K and quarterly 10-Q filings. The company reported positive net income and earnings per share for the fiscal year ending 2025. It maintains liquidity with cash and cash equivalents reported at approximately $12.6 million as of late 2018. The company also manages its capital structure through debt issuance, including subordinated notes issued in 2025.

Harvard Ave Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its sole business activity since inception has been to raise capital through an IPO and private placement to fund a future business combination. The company has no operating business or revenue and holds IPO proceeds in a trust account invested in U.S. government treasury bills or money market funds. The management team brings significant expertise in private equity, investment management, and financial advisory to source and evaluate potential acquisition targets. The company’s acquisition criteria focus on partnering with strong management teams, targeting businesses with long-term revenue visibility and defensible market positions, and leveraging the benefits of being a U.S. public company. As of the latest filings, no target business has been identified or engaged for a business combination. The company’s financial position shows liquidity and net income derived from interest on trust account investments, offset by operating costs related to formation and administration.

Energous Corp is a technology company specializing in wireless power solutions, including innovative battery-free smart tags designed for real-time supply chain monitoring. The company has demonstrated strong revenue growth in 2025, supported by strategic product launches and contract awards. It operates as an emerging growth company and maintains a strong liquidity position as of the end of 2025.

HA Sustainable Infrastructure Capital, Inc. operates as an investment firm specializing in sustainable infrastructure assets. The company targets income-generating assets with long-term recurring cash flows, contracted with creditworthy off-takers, and based on proven commercial technologies. HASI manages a diversified portfolio including equity method investments, receivables, real estate, and securitized assets. The company has a significant pipeline of investment opportunities across various sustainable infrastructure sectors such as solar, renewable natural gas, energy efficiency, and battery storage. Financing strategies include a combination of cash, unsecured and secured debt, equity, and off-balance sheet structures. HASI emphasizes sustainability by quantifying carbon emissions avoided through its investments and aligning financing with green bond principles. The company has demonstrated growth in managed assets and maintains a focus on long-term client relationships and risk-adjusted returns.

Pioneer Acquisition I Corp operates as a special purpose acquisition company (SPAC) with the objective of effecting a merger, share exchange, asset acquisition, or similar business combination with one or more businesses, focusing on healthcare or healthcare-related sectors. The company has not yet identified a target and has no operating revenues. Its management team brings decades of experience in healthcare, financial services, and capital markets, aiming to leverage their network and expertise to identify and execute a high-quality business combination. The company completed its IPO in June 2025, raising $253 million, and maintains strong liquidity as of the end of 2025. It has a 24-month window to complete its initial business combination, with possible extensions subject to shareholder approval.

Shoe Carnival, Inc. operates as one of the nation's largest omnichannel retailers of family footwear and accessories, with a 47-year history and public company status since 1993. The company operates 426 stores across 35 states and Puerto Rico under two banners: Shoe Carnival, targeting moderate to low-income families with value-oriented footwear and a high-energy in-store experience, and Shoe Station, targeting a more affluent customer with premium brands and a modern shopping environment. The company acquired Rogan Shoes in Fiscal 2024, integrating 28 stores into the Shoe Station banner. The Shoe Station banner has been the fastest growing in net sales, while the Shoe Carnival banner and the broader family footwear industry have experienced comparable store sales declines. The company is executing a rebanner strategy to convert Shoe Carnival stores to Shoe Station stores, which has impacted near-term profitability due to store closures and investments. The company announced a proposed corporate name change to Shoe Station Group, Inc. to reflect this strategic focus. Shoe Carnival operates an omnichannel platform with e-commerce sales representing about 10% of merchandise sales, supported by a third-party order management system and ship-from-store fulfillment. The company maintains a vendor drop-ship program and a loyalty program, Shoe Perks, which drives approximately 78% of comparable store net sales. The product assortment covers a broad family footwear mix with key vendors including Nike, Skechers, and Crocs. The company ended Fiscal 2025 with strong liquidity, no debt, and announced a $50 million share buyback program and quarterly dividend. The retail footwear market is highly competitive, with Shoe Carnival competing against mass merchandisers, off-price retailers, department stores, and e-commerce players.

Aptevo Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic product candidates. The company currently has no approved products and generates no product revenue. Its pipeline includes mipletamig and ALG.APV-527, both developed on the ADAPTIR platform. Aptevo relies on third-party manufacturers for production and faces the typical risks of clinical-stage biotech firms, including regulatory approval, clinical trial execution, and capital requirements. The company reported a net loss of $26.0 million for the fiscal year ended December 31, 2025, and has substantial doubt about its ability to continue as a going concern. It has entered into equity purchase agreements providing potential capital but remains exposed to market and operational risks.

Apex Treasury Corporation is a special purpose acquisition company (SPAC) established to effect a merger or similar business combination with one or more target businesses within a 24-month period following its IPO. The company raised approximately $344.7 million in gross proceeds from its IPO in October 2025, which are held in a Trust Account to fund the Business Combination. The company has not yet identified a definitive target and has not generated operating revenues. Its management team and advisory board bring extensive experience in capital markets, M&A, and targeted industries such as blockchain, AI, and renewable energy. The company’s strategy focuses on sourcing undervalued opportunities globally, leveraging strong networks and secular trends in digital assets and capital markets. The Business Combination must meet Nasdaq rules requiring at least 80% of Trust Account assets in fair market value and receive independent director approval. The company may finance the transaction through cash, securities, debt, or equity issuances. Apex Treasury maintains strong liquidity and working capital to support its operations and transaction costs.

Vroom, Inc. was incorporated in 2012 and has evolved from operating an end-to-end ecommerce platform for used vehicles to focusing on automotive finance and AI-powered analytics services. The company completed its IPO in June 2020 and acquired CarStory in 2021 and UACC in 2022. In January 2024, Vroom announced a value maximization plan that led to the wind-down of its ecommerce used vehicle dealership business by March 2024. The company filed for and emerged from a Prepackaged Chapter 11 bankruptcy in late 2024 and early 2025, restructuring its debt and equity. Currently, Vroom operates two main segments: UACC, an indirect lender providing vehicle financing primarily to non-prime consumers through a network of dealerships, and CarStory, which offers AI-driven analytics and digital retailing services to automotive industry clients. UACC services a large portfolio of retail installment sales contracts and funds its operations through warehouse credit facilities and securitizations. CarStory leverages extensive vehicle data and AI to provide pricing and market insights. The company’s financials reflect ongoing losses and a focus on liquidity preservation and operational restructuring.

Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company specializing in molecular diagnostic test kits for transplanted organ rejection. Their decentralized testing approach enables hospitals, transplant centers, and labs to perform in-house testing, contrasting with traditional centralized lab models. The company's flagship technology measures donor-derived cell-free DNA (dd-cfDNA) as a biomarker for organ rejection. Their product portfolio under the GraftAssure brand includes laboratory developed tests (LDTs), research use only (RUO) kits, and in vitro diagnostic (IVD) kits in development. iMDx operates a CLIA and CAP accredited laboratory in Franklin, Tennessee, and research centers in Nashville and Germany. The company also focuses on oncology diagnostics and provides assay development services. iMDx has a strategic partnership with Bio-Rad Laboratories for product development and commercialization. The company is actively pursuing FDA marketing authorization for its IVD products and relies on Medicare reimbursement for commercial viability. It has incurred operating losses since inception and finances operations primarily through equity sales.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2018, focusing on developing novel therapies for immunological diseases, particularly B-cell-driven autoimmune disorders. Its lead candidate, miv-cel, is in Phase 2 clinical trials targeting stiff person syndrome, with additional CAR T-cell therapies under development for autoimmune indications such as generalized myasthenia gravis. The company has no approved products or commercial revenue and has incurred significant net losses since inception. Kyverna relies on third-party manufacturers for production and faces competition from established pharmaceutical companies with approved therapies. The company has raised capital through equity offerings to support its research and development activities and maintains strong liquidity as of the end of 2025. Regulatory scrutiny, including FDA safety communications on CAR T-cell therapies, and the inherent risks of clinical development are material considerations for its business.

BTCS Inc. is a U.S.-based blockchain technology company listed on Nasdaq, specializing in revenue generation through blockchain infrastructure and decentralized finance (DeFi) activities primarily on the Ethereum network. The company actively participates in the Ethereum ecosystem by operating validator nodes (NodeOps) that perform transaction validation and consensus activities, earning ETH-denominated staking rewards. BTCS also operates proprietary block builders (Builder+) that construct optimized transaction blocks, generating fees when these blocks are proposed on-chain. In 2025, BTCS expanded into DeFi operations through its Imperium business line, deploying digital assets into decentralized finance protocols to earn variable rewards based on protocol utilization and market conditions. The company completed a strategic repositioning in 2025 to focus exclusively on Ethereum-related activities, discontinuing non-Ethereum operations and legacy platforms. BTCS employs an integrated capital strategy combining decentralized finance mechanisms with traditional capital markets tools to fund and scale its operations. The company prioritizes secure self-custody of digital assets using a combination of cold and hot wallets and limits exposure to third-party custody risks. As of the end of 2025, BTCS reported revenues of $16.49 million and a net loss of $33.35 million, with a current ratio of 3.38, reflecting a liquidity position supported by significant digital asset holdings. The company operates with a small workforce of nine full-time employees, which presents operational risks related to key personnel and scalability. BTCS faces competitive pressures from a diverse set of participants in blockchain infrastructure and DeFi markets and operates in a rapidly evolving technological and regulatory environment. [S1]

Liberty Global Ltd. is a European telecommunications and media company providing broadband internet, video, fixed-line telephony, and mobile communications services primarily in Belgium, Luxembourg, Ireland, the U.K., and the Netherlands through direct operations and joint ventures. The company completed a spin-off of its Swiss operations in late 2024 and acquired a controlling interest in Formula E in 2024. Its networks pass over 29 million homes and serve millions of fixed-line and mobile customers. The company faces competitive pressures, regulatory challenges, and inflationary cost increases across its markets. It recognizes revenue from bundled service packages and employs share-based compensation plans. Liberty Global maintains significant liquidity and has amended its credit facilities recently to extend maturities.

Arcadia Biosciences, Inc. is a consumer goods company focused on science-based innovation, primarily through its Zola coconut water brand acquired in 2021. The company has transitioned away from its prior focus on wheat trait development and commercialization, having sold related assets and intellectual property in 2024 and 2025. Arcadia's current product portfolio centers on beverage products sourced from Thailand and distributed across the U.S. The company has engaged in strategic transactions including a terminated merger agreement with Roosevelt Resources. Arcadia operates with a small employee base and maintains its headquarters in Dallas, Texas.

P3 Health Partners Inc. operates as a patient-centered, physician-led population health management company primarily serving the Medicare Advantage market in the United States. The company employs a value-based care model that contracts with local physicians through an affiliate network, preserving physician independence and existing patient relationships. P3 receives capitated payments from health plans and manages the total cost of care to improve clinical outcomes and reduce healthcare spending. The company leverages a proprietary technology platform, P3 Technology/Health Hub, to integrate clinical and claims data, enabling risk stratification and personalized care management. As of December 31, 2025, P3 had contracts with 24 health plans across four states and approximately 2,400 primary care physicians in its network. The company reported operating revenue of $1.46 billion for 2025 but incurred a net loss attributable to controlling interest of $147.9 million. Liquidity challenges are evident with a working capital deficit and substantial debt obligations. P3's growth strategy includes expanding its footprint through existing payor relationships, geographic expansion, and potential acquisitions. The company operates in a competitive environment dominated by traditional fee-for-service models and other population health management firms.

Gain Therapeutics, Inc. is a biotechnology company incorporated in Delaware in 2020 and publicly traded on Nasdaq under ticker GANX. The company develops novel small molecule therapeutics targeting diseases caused by protein misfolding, including central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. Its lead clinical-stage product candidate, GT-02287, is being developed for Parkinson's disease with and without GBA1 mutations. Preclinical studies have demonstrated mechanisms of action and safety, and Phase 1 clinical trials have shown safety and tolerability. The company uses its proprietary Magellan™ drug discovery platform to identify allosteric binding sites and develop pipeline programs. Gain Therapeutics operates as a single segment focused on research and development. The company has incurred recurring losses and negative cash flows since inception and funds operations primarily through equity financings and research grants. As of December 31, 2025, it held $20.8 million in cash and equivalents with a strong current ratio, but management is actively seeking additional capital to support operations beyond early 2026. A legal proceeding alleging breach of contract related to warrant repricing is pending, with the company defending the claims.

Allegiant Travel Company operates as a U.S.-based airline with a focus on leisure travel markets. The company reported revenues of approximately $2.61 billion for fiscal year 2025 but incurred a net loss of $44.7 million. Allegiant maintains liquidity with cash and equivalents of $172.7 million and current assets of $967.7 million against current liabilities of $1.02 billion as of year-end 2025. The company’s operating margin was 5.7%, improving to 7.4% on an adjusted basis excluding special charges. Allegiant’s leadership team includes CEO Gregory C. Anderson and Chairman Maurice J. Gallagher, Jr., both with extensive airline industry experience. The company is actively pursuing growth through a merger with Sun Country Airlines, valued at $1.5 billion, which has received regulatory approval. The merger is structured as a two-step process resulting in Sun Country becoming a wholly owned subsidiary. Allegiant’s business model includes a significant frequent flyer program and co-brand credit card partnerships. Recent industry conditions show strong travel demand despite rising fuel costs, with the company adjusting its first quarter 2026 guidance to reflect these dynamics.

Acumen Pharmaceuticals, Inc. is focused on developing disease-modifying therapies for Alzheimer's disease by targeting soluble amyloid-beta oligomers (AβOs), which are believed to be a primary toxin in AD pathology. The company's lead candidate, sabirnetug, is a humanized monoclonal antibody designed to selectively bind AβOs with high specificity, avoiding amyloid plaques and monomers. Sabirnetug has completed Phase 1 clinical trials demonstrating safety, tolerability, and target engagement, and is currently in a Phase 2 trial (ALTITUDE-AD) enrolling patients with early AD. The company is also developing subcutaneous formulations and enhanced brain delivery technologies through collaborations. Financially, Acumen holds substantial cash and investments to fund operations into early 2027 but continues to report net losses typical of clinical-stage biopharmaceutical companies. The company faces risks common to drug development, including clinical trial outcomes, regulatory approvals, funding requirements, and competitive landscape.

Lands' End, Inc. is an apparel company with a notable presence in uniform manufacturing and digital retail channels. The company reported over $1.1 billion in revenue for fiscal 2025 and maintains liquidity with a current ratio of 1.61 as of January 30, 2026. Legal challenges related to product claims have been largely resolved in the company's favor. Recent operational updates highlight mixed financial results with growth in digital sales segments.

AmpliTech Group, Inc. is a Nevada-based company publicly traded on Nasdaq under the ticker AMPG. The company operates in the technology sector with a focus on advanced communications and computing technologies, including quantum computing and 5G connectivity. It offers common stock and associated rights and warrants. The company reported $25.2 million in revenue for fiscal year 2025 but incurred a net loss of $7.0 million. Liquidity metrics as of year-end 2025 show a current ratio of 1.68 and cash ratio of 0.35, indicating moderate short-term financial flexibility. AmpliTech has recently raised capital through a direct stock offering and maintains executive leadership with structured compensation tied to financial and operational performance metrics. The company has secured significant follow-on orders from a Tier-1 North American mobile operator and holds patents related to its technology innovations.

Nortech Systems Incorporated, founded in 1990 and headquartered in Maple Grove, Minnesota, provides engineering design and manufacturing solutions for complex electromedical devices and electromechanical systems. The company operates manufacturing facilities in the United States, Mexico, and China, offering a full range of services including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market support. Its customer base consists mainly of OEMs in the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial sectors, with over half of net sales derived from medical-related markets. Nortech emphasizes quality certifications such as ISO 9001, ISO 13485, AS9100, and FDA registration, and is transitioning its business model toward solution-based offerings with value-added inventory management. The company invests in fiber optic technologies and maintains a diversified customer base, though it has significant customer concentration. Financially, Nortech reported $12.6 million revenue for the first nine months of 2025 and a net loss of $252,000 for the full year. It manages liquidity with a current ratio of 1.88 and maintains a revolving credit facility maturing in 2029. Risks include supply chain disruptions, customer order variability, labor retention, and financial covenant compliance. Recent developments include a challenging Q3 with strategic restructuring and prior trading interruptions.

Reliance Global Group, Inc. is a publicly traded company on NASDAQ (ticker EZRA) headquartered in Florida, operating primarily in the insurance brokerage and InsurTech sectors. The company offers insurance brokerage services and operates the RELI Exchange platform, which facilitates the sale of health insurance and personal lines property and casualty insurance policies. The company has been actively expanding its business through acquisitions, capital raises, and strategic investments, including a milestone-based acquisition of a majority stake in Enquantum Ltd., an AI breath diagnostics firm. Reliance Global Group has reported significant growth in insurance policies written through its platform, including a 72% increase in health insurance policies and a 36% increase in personal lines property and casualty premiums year-over-year during 2025. The company has also taken steps to reduce its long-term debt and improve liquidity, with reported cash and equivalents of approximately $10 million and a current ratio of 1.78 as of the end of 2025. The company is executing a OneFirm Strategy aimed at transforming its operations and enhancing revenue opportunities, including launching new services such as RELI Auto Leasing.

Spero Therapeutics, Inc. operates in the biotechnology sector with a focus on developing novel treatments for rare diseases and infections caused by multidrug-resistant bacteria. The company has reprioritized its pipeline, discontinuing SPR206 and SPR720 programs to concentrate resources on the tebipenem HBr program, which is being developed in partnership with GlaxoSmithKline (GSK). Spero relies on third-party manufacturers primarily located in Asia for clinical and potential commercial production, which introduces supply chain and geopolitical risks. The company currently has no approved products and recognizes revenue mainly through licensing and collaboration agreements, including milestone payments and royalties. Financially, as of the fiscal year ending December 31, 2025, Spero reported revenues of approximately $66.8 million and net income of $8.6 million, supported by a strong liquidity position with a current ratio of 7.59. The company is classified as a smaller reporting company and continues to face typical biotech risks related to clinical development, regulatory approval, and partnership dependencies.

Upstream Bio, Inc. focuses on developing treatments for inflammatory diseases, primarily severe respiratory disorders. Its lead product candidate, verekitug, is a highly potent monoclonal antibody that antagonizes the TSLP receptor, a validated target upstream in inflammatory signaling pathways. Verekitug is in clinical development for severe asthma, CRSwNP, and COPD, with positive Phase 2 data reported for severe asthma and CRSwNP and ongoing Phase 2 COPD trials. The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in early 2027, emphasizing extended dosing intervals and at-home administration. Upstream Bio operates with a team experienced in respiratory disease drug development and relies on third-party manufacturers for production. The company reported a net loss in 2025 but maintains strong liquidity.

Karbon Capital Partners Corp. is a Cayman Islands-incorporated company that completed its initial public offering in December 2025. The IPO involved the issuance of units consisting of Class A ordinary shares and redeemable warrants. The company has established a trust account for IPO proceeds and is classified as an emerging growth company. As of the fiscal year ended December 31, 2025, the company reported positive net income and strong liquidity ratios. The company is not currently involved in any material legal proceedings and maintains risk disclosures consistent with its IPO prospectus.

Dare Bioscience, Inc. is a health biotech company dedicated to advancing women's health by developing science-based solutions addressing unmet needs in contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company employs a dual-path business model that includes pursuing traditional FDA approval for proprietary formulations alongside earlier market access through Section 503B compounding, which allows compounded prescription drugs to be distributed without patient-specific prescriptions. This approach aims to accelerate product availability while maintaining clinical rigor. The company's first FDA-approved product, XACIATO, treats bacterial vaginosis and is commercialized by Organon under license. The company has initiated commercialization of DARE to PLAY Sildenafil Cream, a topical treatment for female sexual arousal disorder, under Section 503B. The pipeline includes Ovaprene, a hormone-free monthly contraceptive in pivotal Phase 3 trials, DARE-HRT1 for menopausal hormone therapy, and DARE-HPV for HPV clearance. Dare Bioscience relies on strategic collaborations for manufacturing, distribution, and commercialization, without owning sales or marketing infrastructure. Financially, the company reported a net loss of $13.4 million for fiscal year 2025, with cash and equivalents of approximately $24.7 million and a current ratio of 1.14 as of December 31, 2025. The company continues to seek capital through equity offerings and grants to support its development programs.

American Bitcoin Corp. is a publicly traded company focused on Bitcoin accumulation through a multi-pronged strategy combining efficient Bitcoin mining, disciplined Bitcoin reserve expansion, and ecosystem engagement. The company operates a large fleet of Bitcoin miners across multiple sites in the U.S. and Canada under agreements with Hut 8, including locations in New York, Alberta, Texas, and Nebraska. It generates revenue by providing computation services to third-party Bitcoin mining pool operators, receiving Bitcoin payouts based on computing power contributed. The company completed a strategic merger with Gryphon Digital Mining in 2025, which expanded its mining capacity and operational footprint. It also launched a $2.1 billion at-the-market equity offering program to raise capital for growth initiatives. The business is sensitive to Bitcoin price volatility, network hashrate and difficulty changes, block reward halving events, and power costs, all of which impact mining profitability and results of operations.

Luminar Technologies, Inc. was a technology company focused on developing advanced Light Detection and Ranging (LiDAR) hardware and software solutions to enable safer and smarter vehicles. The company developed proprietary 1550nm wavelength LiDAR sensors, including the Iris product line, designed to meet demanding automotive safety and autonomy requirements. Luminar also developed semiconductor components in-house through its subsidiary Luminar Semiconductor, Inc., and was working on software capabilities such as perception and high-definition 3D mapping. The company targeted markets including passenger vehicles, commercial trucks, robo-taxis, and adjacent sectors like aerospace and defense. However, commencing in February 2026, Luminar ceased business operations and is in the process of winding down following Chapter 11 bankruptcy proceedings filed in December 2025. The company sold its semiconductor business to Quantum Computing Inc. and its LiDAR assets to MicroVision in early 2026 [S1][N2].

BitGo Holdings, Inc. aims to be the preferred digital asset infrastructure provider for institutional clients, enabling secure custody, management, utilization, and creation of digital assets through a unified technology platform. The company’s platform is structured into four layers: self-custody wallet solutions leveraging patented multi-sig and MPC technology; qualified custody solutions with fiduciary duties and bankruptcy-remote segregated accounts; liquidity and prime solutions including staking, trading, lending, and collateral management; and infrastructure-as-a-service offerings such as Stablecoin-as-a-Service and Crypto-as-a-Service. BitGo serves a diverse client base including crypto-native companies, traditional financial institutions, fintech platforms, corporations, government agencies, and high net worth individuals across more than 100 countries. The company emphasizes security, regulatory compliance, and trust, operating under a federally chartered national trust bank and holding significant Bitcoin treasury reserves. Its revenue streams are diversified across trading volume, staking rewards, subscription fees, stablecoin services, and interest income. BitGo’s platform benefits from network effects and aims to expand its market presence and product offerings globally.

FG Nexus Inc., formerly Fundamental Global Inc., is a Nevada-incorporated holding company listed on Nasdaq under FGNX and FGNXP. It operates primarily through two segments: digital assets and merchant banking. The digital assets segment manages a treasury focused on Ethereum (ETH) and tokenization of real-world assets such as affordable housing and real estate. The merchant banking segment provides strategic and regulatory support to SPACs and has co-founded partnerships to sponsor SPACs and other clients. The company has divested its reinsurance business and transferred its managed services subsidiary to a trust. Corporate actions include a 1-for-5 reverse stock split effective February 2026, a $200 million common stock repurchase program, and a private placement raising over $176 million in cash and cryptocurrency. As of December 31, 2025, the company held approximately 40,093 ETH valued at $119.4 million and employed 15 full-time staff. Financial results include $9.1 million revenue for the first half of 2025 and net income of $1.1 million in 2022, with a negative EPS reported for 2025.

Phunware, Inc. is a technology company publicly traded on Nasdaq under the ticker PHUN. The company has filed recent SEC reports including a 10-K for fiscal year 2025 and a 10-Q for the third quarter of 2025, which provide financial data and risk disclosures. As of December 31, 2025, Phunware held significant cash reserves and current assets relative to liabilities, indicating strong liquidity. The company has reported net losses in recent periods but continues to develop and introduce new AI-driven features targeting mobile guest engagement in hospitality. Leadership changes occurred in 2025 with an interim CEO appointment and a new executive chairman role focused on AI architecture.

SpringBig Holdings, Inc. operates a comprehensive SaaS platform that provides loyalty, digital communications, and marketing automation solutions tailored to cannabis retailers and brands. The platform enables clients to engage consumers through SMS, email, and push notifications, offering loyalty programs including premium tiers and prepaid gift card payment options. SpringBig's technology integrates with leading cannabis point-of-sale and e-commerce systems to provide actionable consumer data and analytics. The company serves a broad client base across all legalized cannabis markets in the U.S. and Canada, with plans to expand into new regulated markets. Revenue is primarily subscription-based, supplemented by brand advertising and revenue sharing arrangements. The company faces challenges from evolving cannabis marketing regulations and carrier restrictions but has developed proprietary compliant solutions to maintain communication channels. As of December 31, 2025, SpringBig reported $22.8 million in revenue and a net loss of $3.25 million, with liquidity ratios indicating working capital constraints. The company employs 56 staff and maintains sales and client service operations in the U.S. and Canada.

Republic Digital Acquisition Co is a Cayman Islands exempted blank check company incorporated in January 2025. It completed an IPO in May 2025, raising $300 million through the issuance of Units consisting of Public Shares and Warrants. The company’s purpose is to identify and consummate a Business Combination with one or more target businesses, primarily focusing on industries aligned with its management team’s expertise in fintech, software, and cryptocurrency. The company has not generated operating revenues and is currently in the search phase for a suitable Business Combination target. It holds substantial cash and current assets with strong liquidity as of the end of 2025. The company must complete its Business Combination by May 1, 2027, or face liquidation and distribution of trust account funds to shareholders. The management team and sponsor have experience in digital asset management and finance, and the company is sponsored by Republic Sponsor 1 LLC, majority owned by Feynman Point Asset Management LLC.

Hydrofarm Holdings Group, Inc. is a publicly traded company listed on Nasdaq under the ticker HYFM. The company operates in the agriculture-related sector, focusing on products and services related to AgTech and food innovation, as inferred from recent news coverage. Hydrofarm has reported significant net losses and liquidity challenges in recent financial periods, with a net loss of approximately $289.8 million for the fiscal year ended December 31, 2025. The company holds limited cash and current assets relative to its current liabilities, resulting in liquidity ratios below 1.0. Hydrofarm has been actively managing its capital structure, including terminating its revolving credit agreement and engaging with lenders on its senior secured term loans. The company continues to face operational and financial challenges as reflected in recent quarterly results and ongoing strategic reviews.

Senti Biosciences, Inc. operates as a clinical-stage biotechnology company developing advanced cell and gene therapies engineered with proprietary gene circuit technologies. These gene circuits enable therapeutic cells to sense, compute, and respond to disease environments with enhanced precision and control. The company’s lead candidate, SENTI-202, is a Logic Gated CAR-NK cell therapy designed to selectively target AML and other hematologic malignancies by recognizing tumor-associated antigens CD33 and FLT3 while sparing healthy hematopoietic stem cells through an inhibitory CAR targeting EMCN. SENTI-202 is undergoing Phase 1 clinical trials in the US and Australia, showing promising response rates and safety profiles. The company’s platform includes multiple gene circuit categories applicable across various cell types and therapeutic modalities, with ongoing efforts to expand pipeline and partnerships. Financially, Senti Biosciences has incurred significant losses typical of early-stage biotech firms, with moderate liquidity as of the end of 2025.